Insulin-like growth factor pathway polymorphisms associated with body size in Hispanic and non-Hispanic white women

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 7, 2005, Pages 1802-1809

  Sweeney, Carol ^a,f   Murtaugh, Maureen A ^a   Baumgartner, Kathy B ^b   Byers, Tim ^c   Giuliano, Anna R ^d   Herrick, Jennifer S ^a   Wolff, Roger ^a   Caan, Bette J ^e   Slattery, Martha L ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e DIVISION OF RESEARCH   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; GLYCINE; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; VITAMIN D RECEPTOR;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; BODY SIZE; CANCER; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GROWTH; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PHENOTYPE; PRIORITY JOURNAL; UNITED STATES; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; AGED; BODY SIZE; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HISPANIC AMERICANS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, INSULIN; SOMATOMEDINS; SOUTHWESTERN UNITED STATES;

EID: 22244467995     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0149     Document Type: Article

References (72)

1. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
2. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
3. Polymeropoulos MH, Rath DS, Xiao H, Merril CR. Dinucleotide repeat polymorphism at the human gene for insulin-like growth factor I (IGFI). Nucleic Acids Res 1991;19:5797.
4. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for generic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
5. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637-42.
6. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 2004;13:1444-51.
7. Missmer SA, Haiman CA, Hunter DJ, et al. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 2002;100: 332-6.
8. Rietveld I, Janssen JA, van Rossum EF, et al. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clin Endocrinol (Oxf) 2004; 61:195-203.
9. Kato I, Eastham J, Li B, Smith M, Yu H. Genotype-phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. Eur J Epidemiol 2003;18:203-9.
10. Arends N, Johnston L, Hokken-Koelega A, et al. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 2002;87:2720.
11. Sun G, Gagnon J, Chagnon YC, et al. Association and linkage between an insulin-like growth factor-1 gene polymorphism and fat free mass in the HERITAGE Family Study. Int J Obes Relat Metab Disord 1999;23:929-35.
12. Wen W, Gao YT, Shu XO, et al. Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women. Int J Cancer 2005;113:307-11.
13. Fletcher O, Gibson L, Johnson N, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:2-19.
14. Tsuchiya N, Wang L, Horikawa Y, et al. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol 2005;26:225-31.
15. Friedrichsen DM, Hawley S, Shu J, et al. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate 2005;64:68-74.
16. Li L, Cicek MS, Casey G, Witte JS. No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:497-8.
17. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86: 1274-80.
18. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor- binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-84.
19. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 2003;107:60-4.
20. Ren Z, Cai Q, Shu XO, et al. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 2004;13:1290-5.
21. Wang L, Habuchi T, Tsuchiya N, et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003;63:4407-11.
22. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 1993;342:828-32.
23. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996;97:2569-75.
24. Almind K, Frederiksen SK, Bernal D, et al. Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: evaluation of their relation with alterations in insulin secretion and insulin sensitivity. Diabetologia 1999; 42:1244-9.
25. Kovacs P, Hanson RL, Lee YH, et al. The role of insulin receptor substrate-1 gene (IRS1) in type 2 diabetes in Pima Indians. Diabetes 2003;52:3005-9.
26. Sanchez-Corona J, Flores-Martinez SE, Machorro-Lazo MV, et al. Polymorphisms in candidate genes for type 2 diabetes mellitus in a Mexican population with metabolic syndrome findings. Diabetes Res Clin Pract 2004; 63:47-55.
27. 1057Asp mutation. Hum Genet 2003;113:34-43.
28. Rasmussen SK, Urhammer SA, Hansen T, et al. Variability of the insulin receptor substrate-1, hepatocyte nuclear factor-1α (HNF-1α), HNF-4α, and HNF-6 genes and size at birth in a population-based sample of young Danish subjects. J Clin Endocrinol Metab 2000;85:2951-3.
29. Rice T, Chagnon YC, Perusse L, et al. A genomewide linkage scan for abdominal subcutaneous and visceral fat in Black and White families: the HERITAGE Family Study. Diabetes 2002;51:848-55.
30. Mammarella S, Romano F, Di Valerio A, et al. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Hum Mol Genet 2000;9:2517-21.
31. Florez JC, Sjogren M, Burtt N, et al. Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes. Diabetes 2004;53:3313-8.
32. van Dam RM, Hoebee B, Seidell JC, Schaap MM, Blaak EE, Feskens EJ. The insulin receptor substrate-1 Gly972Arg polymorphism is not associated with Type 2 diabetes mellitus in two population-based studies. Diabet Med 2004; 21:752-8.
33. Clausen JO, Hansen T, Bjorbaek C, et al. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 1995;346:397-402.
34. McGettrick AJ, Feener EP, Kahn CR. Human IRS-1 polymorphism, G972R, causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. J Biol Chem 2004;280:6441-6.
35. Slattery ML, Samowitz W, Curtin K, et al. Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1206-14.
36. Neuhausen SL, Slattery ML, Garner CP, Ding YC, Hoffman M, Brothman AR. Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: Strong association of IRS1 G972R variant and cancer risk. Prostate 2005;64: 168-74.
37. Wagner K, Hemminki K, Grzybowska E, et al. The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer. Cardnogenesis 2004;25:2473-8.
38. Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA. Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states. J Steroid Biochem Mol Biol 2004;89-90:187-93.
39. Welsh J, Wietzke JA, Zinser GM, et al. Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 2002;83:85-92.
40. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 1998;20:157-62.
41. Rozen F, Yang XF, Huynh H, Pollak M. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst 1997;89:652-6.
42. Ingles SA, Halle RW, Henderson BE, et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol Biomarkers Prev 1997;6:93-8.
43. Durrin LK, Haue RW, Ingles SA, Coetzee GA. Vitamin D receptor 3′-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim Biophys Acta 1999;1453:311-20.
44. Thakkinsrian A, D'Este C, Eisman J, Nguyen T, Atria J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res 2004;19:419-28.
45. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004;338:143-56.
46. Tao C, Yu T, Garnett S, et al. Vitamin D receptor alleles predict growth and bone density in girls. Arch Dis Child 1998;79:488-93; discussion 493-4.
47. van der Sluis IM, de Muinck Keizer-Schrama SM, Krenning EP, Pols HA, Uitterlinden AG. Vitamin D receptor gene polymorphism predicts height and bone size, rather than bone density in children and young adults. Calcif Tissue Int 2003;73:332-8.
48. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 1999;83:723-6.
49. Ingles SA, Garcia DG, Wang W, et al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000;11:25-30.
50. Slattery M, Yakumo K, Hoffman M, Neuhausen S. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 2001;12:359-64.
51. Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 2004;13:538-45.
52. Slattery ML, Neuhausen SL, Hoffman M, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 2004;111:750-6
53. Slattery ML, Murtaugh M, Caan B, Ma KN, Wolff R, Samowitz W. Associations between BMI, energy intake, energy expenditure, VDR genotype and colon and rectal cancers (United States). Cancer Causes Control 2004;15:863-72.
54. Wong HL, Seow A, Arakawa K, Lee HP, Yu MC, Ingles SA. Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis 2003;24:1091-5.
55. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer-beyond physical activity. Cancer Res 1997;57:75-80.
56. Slattery ML, Caan BJ, Benson J, Murtaugh M. Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index. Nutr Cancer 2003;46:166-71.
57. Rogers A, Murtaugh MA, Edwards S, Slattery ML. Contacting controls: are we working harder for similar response rates, and does it make a difference? Am J Epidemiol 2004;160:85-90.
58. Howard CA, Samet JM, Buechley RW, Schrag SD, Key CR. Survey research in New Mexico Hispanics: some methodological issues. Am J Epidemiol 1983;117:27-34.
59. Slattery ML, Potter JD, Duncan DM, Berry TD. Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. Int J Cancer 1997;73: 670-7.
60. McDonald A, Van Horn L, Slattery M, et al. The CARDIA dietary history: development, implementation, and evaluation. J Am Diet Assoc 1991;91: 1104-12.
61. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:4297-300.
62. McClure L, Eccleshall TR, Gross C, et al. Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican-American women. J Bone Miner Res 1997;12:234-40.
63. Harris SS, Eccleshall TR, Gross C, Dawson-Hughes B, Feldman D. The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American Black and White women. J Bone Miner Res 1997;12:1043-8.
64. Chagnon YC, Rice T, Perusse L, et al. Genomic scan for genes affecting body composition before and after training in Caucasians from HERITAGE. J Appl Physiol 2001;90:1777-87.
65. Comuzzie AG, Mitchell BD, Cole S, et al. The genetics of obesity in Mexican Americans: the evidence from genome scanning efforts in the San Antonio family heart study. Hum Biol 2003;75:635-46.
66. Arya R, Duggirala R, Jenkinson CP, et al. Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans. Am J Hum Genet 2004;74:272-82.
67. Jernstrom H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin- like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001;72:144-54.
68. Nindl BC, Scoville CR, Sheehan KM, Leone CD, Mello RP. Gender differences in regional body composition and somatotrophic influences of IGF-I and leptin. J Appl Physiol 2002;92:1611-8.
69. Gomez JM, Maravall FJ, Gomez N, Navarro MA, Casamirjana R, Soler J. Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected. Clin Endocrinol (Oxf) 2003;58:213-9.
70. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.
71. Snyder EE, Walts B, Perusse L, et al. The human obesity gene map: the 2003 update. Obes Res 2004;12:369-439.
72. Nejentsev S, Godfrey L, Snook H, et al. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 2004; 13:1633-9.